Inhaled therapy in cystic fibrosis: agents, devices and regimens

Agent Penny, Parrott Helen

Source: Breathe 2015; 11:110-118

Journal Issue: June

Disease area: Airway diseases, Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Agent Penny, Parrott Helen. Inhaled therapy in cystic fibrosis: agents, devices and regimens. Breathe 2015; 11:110-118

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009
Inhaled mannitol as treatment for children with cystic fibrosis Source: Annual Congress 2008 - The use of inhaled mannitol for assessing airway disease Year: 2008
Inhaled antibiotics in cystic fibrosis: what we should do and what we still do not know Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Prescription of Inhaled corticosteroid in non-cystic fibrosis bronchiectasis:a solution or a problem Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020
Inhalation therapy in cystic fibrosis Source: School Course 2013 - Cystic Fibrosis Year: 2013
Inhaled antimicrobials Source: ERS webinar 2020: Inhaled antimicrobials Year: 2020
Use of a new feedback tool to optimize inhaled aerosol therapy in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 261s Year: 2006
Alternating inhaled antibiotic therapy in CF: A single center analysis Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015
Anti-inflammatory therapies in bronchiectasis Source: Eur Respir Mon 2011; 52: 223-238 Year: 2011
Benefit of aerosol therapy with pulmozyme for children with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 622s Year: 2005
Inhaled antibiotic therapy Source: Annual Congress 2013 –PG9 How to optimise antibiotic use in respiratory infections Year: 2013
Inhaled corticosteroids: a controversial add-on treatment in COPD Source: Eur Respir J 2010; 36: 973-974 Year: 2010
Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020
Inhaled steroids in children with non-cystic fibrosis bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 392s Year: 2004
Long-term tiotropium bromide therapy was retrospectively analyzed in adults with cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015
Emerging inhaled bronchodilators: an update Source: Eur Respir J 2009; 34: 757 Year: 2009
Inhaled colistin following lung transplantation in colonised cystic fibrosis patients Source: Eur Respir J 2013; 42: 542-544 Year: 2013